Evidence map›Paper›PMID 35051851›Full record

ArticleBiosensors & bioelectronics2022

Synthetic nanobody-functionalized nanoparticles for accelerated development of rapid, accessible detection of viral antigens.

Xiahui Chen, Shoukai Kang, Md Ashif Ikbal, Zhi Zhao, Yuxin Pan, Jiawei Zuo, Liangcai Gu, Chao Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors & bioelectronics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiahui ChenSchool of Electrical, Computer and Energy Engineering, Arizona State University, Tempe, AZ, 85287, USA; Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ, 85287, USA; Center for Photonic Innovation, Arizona State University, Tempe, AZ, 85287, USA.
Shoukai KangDepartment of Biochemistry, University of Washington, Seattle, WA, 98195, USA; Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA.
Md Ashif IkbalSchool of Electrical, Computer and Energy Engineering, Arizona State University, Tempe, AZ, 85287, USA; Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ, 85287, USA; Center for Photonic Innovation, Arizona State University, Tempe, AZ, 85287, USA.
Zhi ZhaoSchool of Electrical, Computer and Energy Engineering, Arizona State University, Tempe, AZ, 85287, USA; Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ, 85287, USA.
Yuxin PanDepartment of Biochemistry, University of Washington, Seattle, WA, 98195, USA; Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA.
Jiawei ZuoSchool of Electrical, Computer and Energy Engineering, Arizona State University, Tempe, AZ, 85287, USA; Center for Photonic Innovation, Arizona State University, Tempe, AZ, 85287, USA.
Liangcai GuDepartment of Biochemistry, University of Washington, Seattle, WA, 98195, USA; Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA. Electronic address: gulc@uw.edu.
Chao WangSchool of Electrical, Computer and Energy Engineering, Arizona State University, Tempe, AZ, 85287, USA; Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, AZ, 85287, USA; Center for Photonic Innovation, Arizona State University, Tempe, AZ, 85287, USA. Electronic address: wangch@asu.edu.

Funding

De Novo Engineering of Small Molecule-Actuatable Biosensors for Cell TherapyR35GM128918 · NIGMS · UNIVERSITY OF WASHINGTON · PI GU, LIANGCAI · 2018 to 2022
$2.1M
NIGMS NIH HHS R35 GM128918
6 · The paper itself

Abstract

Successful control of emerging infectious diseases requires accelerated development of fast, affordable, and accessible assays for wide implementation at a high frequency. This paper presents a design for an in-solution assay pipeline, featuring nanobody-functionalized nanoparticles for rapid, electronic detection (Nano2RED) of Ebola and COVID-19 antigens. Synthetic nanobody binders with high affinity, specificity, and stability are selected from a combinatorial library and site-specifically conjugated to gold nanoparticles (AuNPs). Without requiring any fluorescent labelling, washing, or enzymatic amplification, these multivalent AuNP sensors reliably transduce antigen binding signals upon mixing into physical AuNP aggregation and sedimentation processes, displaying antigen-dependent optical extinction readily detectable by spectrometry or portable electronic circuitry. With Ebola virus secreted glycoprotein (sGP) and a SARS-CoV-2 spike protein receptor binding domain (RBD) as targets, Nano2RED showed a high sensitivity (the limit of detection of ∼10 pg /mL, or 0.13 pM for sGP and ∼40 pg/mL, or ∼1.3 pM for RBD in diluted human serum), a high specificity, a large dynamic range (∼7 logs),and fast readout within minutes. The rapid detection, low material cost (estimated <$0.01 per test), inexpensive and portable readout system (estimated <$5), and digital data output, make Nano2RED a particularly accessible assay in screening of patient samples towards successful control of infectious diseases.

Indexed as

Biosensing TechniquesCOVID-19Metal NanoparticlesAntigens, ViralEbolavirusGlycoproteinsGoldHumansSARS-CoV-2Spike Glycoprotein, CoronavirusViral ProteinsAntigens, ViralGlycoproteinsGoldSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral ProteinsCo-binding nanobodiesCOVID-19Ebola virusInfectious diseasesMetal nanoparticlesRapid electronic detection

Identifiers

PMID35051851
PMCPMC8734080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.